Purpose of study: 

To assess efficacy and safety of Kv9 across a range of solid tumours. 

​

Eligible tumour types: 

• Soft tissue sarcomas 

• Mast cell tumours 

• Mammary gland tumours

• Melanomas 

• Anal gland tumours 

• Squamous cell carcinomas 

• Other tumours may be considered 

​

Primary eligibility criteria*: ​

• Tumour type diagnosed by fine needle aspirate or biopsy by a registered veterinary pathologist 

• ​Tumour (approximately) measurements between 1cm and 5cm at the widest point

• Not receiving chemotherapy or immune modulatory drugs

  • It is acceptable to be taking/receiving including apoquel, cytopoint, beranza or a recent vaccination 

• No wounds on the surface of soft tissue sarcoma tumours

  • Other tumour types will be a case by case basis ​

*See referral form for complete criteria 

​

Treatment centres: 

• Auckland

  • Onewa Road Veterinary Hospital

  • CareVets Glen Eden ​

  • Remuera Veterinary Clinic & Hospital 

• Hamilton 

  • CareVets Rototuna ​

• Bay of Plenty 

  • Location pending ​

• Hawkes Bay 

  • Vet Services Napier ​

  • Vet Services Dannevirke

• Wellington 

  • Rappaw Central Veterinary Hospital ​

  • CareVets Kilbirnie 

​

​

Study protocol: 

1. Primary veterinarian to send through referral for assessment by Kode Veterinary Sciences (KVS). 

2. Additional testing completed as required. 

3. Up to three treatment appointments to receive Kv9 at treatment centres.

4. A minimum of 9 revisits at primary care veterinarian or treatment centres over 2 years. 

​

Owner responsibilities: 

• You are responsible to schedule and attend all required visits  ​

• You are responsible for the initial costs to diagnose your dogs tumour, and any other tests recommended by your veterinarian  

• You are responsible to closely monitor your pet for any changes and update the clinical study team in a timely manner 

​

Financial support: 

• There is no cost to participate in the clinical study. KVS will cover the cost of treatment and monitoring appointments, and provide the Kv9 treatment free of charge. 

• KVS will provide support to any participant experiencing adverse events during their time in the trial. If the event is suspected to be related to the Kv9 treatment, KVS will provide financial support, unless agreed to be excluded in the consent form.  

​